Announcements Trials

Browse Landscape

Phase

Status

Unknown 4 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Small Cell Lung Carcinoma 3 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Advanced Cancer 2 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Stereotactic Body Radiation Therapy 1 Sarcoma 1 Recurrence 1 Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1 Pheochromocytoma 1 Paraganglioma, Extra-Adrenal 1 Paraganglioma 1 Pancreatic Neoplasms 1 NSCLC 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colonic Neoplasms 1 Carcinoma, Medullary 1 Brain Neoplasms 1 Advanced Solid Tumors 1 Advanced Malignancy 1 Advanced Endometrial Cancer 1 Adenocarcinoma of Lung 1

Interventions

Carboplatin 41 Paclitaxel 40 pembrolizumab 38 Cyclophosphamide 23 Gemcitabine 22 130-nm albumin-bound paclitaxel 21 Doxorubicin 18 Cisplatin 18 Albumin-Bound Paclitaxel 18 atezolizumab 16 Taxes 15 Capecitabine 13 veliparib 10 Nivolumab 9 Docetaxel 9 Bevacizumab 9 olaparib 8 liposomal doxorubicin 7 Everolimus 7 spartalizumab 6 durvalumab 6 Epirubicin 6 trametinib 5 pegfilgrastim 5 eribulin 5 Irinotecan 5 Filgrastim 5 iniparib 4 binimetinib 4 apatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Triple Negative Breast Neoplasms × anlotinib × Clear all

NCT04877821 2026-04-02

NeoSACT

Guangdong Provincial People's Hospital

Phase 2 Completed

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡